{"id": "patient_01_q0", "query": "Which of the following is NOT part of the current treatment regimen for Mrs. Sample's DLBCL?", "options_scores": {"A": 0.8261992931365967, "B": 1.1009341478347778, "C": 1.0877292156219482, "D": 3.6875104904174805, "E": 1.8573122024536133}, "ranked_options": [{"letter": "A", "text": "Polatuzumab vedotin", "avg_nll": 0.8261992931365967}, {"letter": "C", "text": "Cyclophosphamide", "avg_nll": 1.0877292156219482}, {"letter": "B", "text": "Rituximab", "avg_nll": 1.1009341478347778}, {"letter": "E", "text": "Doxorubicin", "avg_nll": 1.8573122024536133}, {"letter": "D", "text": "Vincristine", "avg_nll": 3.6875104904174805}], "correct_answer_letter": "D", "error": null, "method": "local"}
{"id": "patient_01_q1", "query": "In the context of Mrs. Sample's other diagnoses, which of the following is NOT accurate based on the provided information?", "options_scores": {"A": 3.1317331790924072, "B": 1.1683357954025269, "C": 1.951003074645996, "D": 2.2468533515930176, "E": 2.243579387664795}, "ranked_options": [{"letter": "B", "text": "She was diagnosed with primary progressive type of multiple sclerosis.", "avg_nll": 1.1683357954025269}, {"letter": "C", "text": "She has a mood disorder.", "avg_nll": 1.951003074645996}, {"letter": "E", "text": "She has pre-existing ALS.", "avg_nll": 2.243579387664795}, {"letter": "D", "text": "She has 3-vessel CHD.", "avg_nll": 2.2468533515930176}, {"letter": "A", "text": "She has 2-vessel disease", "avg_nll": 3.1317331790924072}], "correct_answer_letter": "D", "error": null, "method": "local"}
{"id": "patient_01_q2", "query": "Which chronic, neuroinflammatory disease does Mrs. Sample suffer from? ", "options_scores": {"A": 2.133913040161133, "B": 6.071162700653076, "C": 10.228017807006836, "D": 5.73186731338501, "E": 2.5870397090911865}, "ranked_options": [{"letter": "A", "text": "Multiple sclerosis", "avg_nll": 2.133913040161133}, {"letter": "E", "text": "Autoimmune encephalitis", "avg_nll": 2.5870397090911865}, {"letter": "D", "text": "Brain abscess", "avg_nll": 5.73186731338501}, {"letter": "B", "text": "Dementia", "avg_nll": 6.071162700653076}, {"letter": "C", "text": "Parkinson", "avg_nll": 10.228017807006836}], "correct_answer_letter": "A", "error": null, "method": "local"}
{"id": "patient_01_q3", "query": "Mrs. Sample takes Fingolimod. What is the dosis and when does the patient take it?", "options_scores": {"A": 1.702875018119812, "B": 1.74044930934906, "C": 1.779685616493225, "D": 2.3795220851898193, "E": 2.3880512714385986}, "ranked_options": [{"letter": "A", "text": "0.5 mg, 1 capsule in the morning", "avg_nll": 1.702875018119812}, {"letter": "B", "text": "0.5 mg, 1 capsule at bedtime", "avg_nll": 1.74044930934906}, {"letter": "C", "text": "50 mg, 1 capsule in the morning", "avg_nll": 1.779685616493225}, {"letter": "D", "text": "35 mg, 1 capsule at bedtime", "avg_nll": 2.3795220851898193}, {"letter": "E", "text": "70 mg, 1 capsule in the morning", "avg_nll": 2.3880512714385986}], "correct_answer_letter": "B", "error": null, "method": "local"}
{"id": "patient_01_q4", "query": "Which therapy regime does the oncology board recommend for Mrs. Sample?", "options_scores": {"A": 5.7036004066467285, "B": 5.799165725708008, "C": 4.943066120147705, "D": 1.8248354196548462, "E": 5.315824031829834}, "ranked_options": [{"letter": "D", "text": "6 cycles of R-Pola-CHP", "avg_nll": 1.8248354196548462}, {"letter": "C", "text": "6 cycles of L-Pola-CRP", "avg_nll": 4.943066120147705}, {"letter": "E", "text": "8 cycles of M-Pola-CHZ", "avg_nll": 5.315824031829834}, {"letter": "A", "text": "5 cycles of T-Pola-RHP", "avg_nll": 5.7036004066467285}, {"letter": "B", "text": "7 cycles of R-Luna-CHT", "avg_nll": 5.799165725708008}], "correct_answer_letter": "D", "error": null, "method": "local"}
{"id": "patient_01_q5", "query": "Mrs. Sample has bone metastasis, of which one was surgically addressed. Where was this metastasis located? ", "options_scores": {"A": 3.057981252670288, "B": 3.0311954021453857, "C": 1.665118932723999, "D": 1.555743932723999, "E": 2.626056432723999}, "ranked_options": [{"letter": "D", "text": "Thoracic vertebra 11", "avg_nll": 1.555743932723999}, {"letter": "C", "text": "Thoracic vertebra 10", "avg_nll": 1.665118932723999}, {"letter": "E", "text": "Thoracic vertebra 12", "avg_nll": 2.626056432723999}, {"letter": "B", "text": "Thoracic vertebra 9", "avg_nll": 3.0311954021453857}, {"letter": "A", "text": "Thoracic vertebra 8", "avg_nll": 3.057981252670288}], "correct_answer_letter": "C", "error": null, "method": "local"}
{"id": "patient_01_q6", "query": "On 01/09/2017, Mrs. Sample received a CT scan of her whole body. What kind of contrast agent was used?", "options_scores": {"A": 3.416215419769287, "B": 3.1038119792938232, "C": 2.0253288745880127, "D": 2.717235565185547, "E": 3.448953628540039}, "ranked_options": [{"letter": "C", "text": "Optiray 320", "avg_nll": 2.0253288745880127}, {"letter": "D", "text": "Gadovist", "avg_nll": 2.717235565185547}, {"letter": "B", "text": "Imeron 400", "avg_nll": 3.1038119792938232}, {"letter": "A", "text": "Omnipaque 320", "avg_nll": 3.416215419769287}, {"letter": "E", "text": "Xenetix 350", "avg_nll": 3.448953628540039}], "correct_answer_letter": "A", "error": null, "method": "local"}
{"id": "patient_01_q7", "query": "Mrs. Sample received multiple radiologic examinations. In which order did she receive them?", "options_scores": {"A": 2.3911921977996826, "B": 1.7155495882034302, "C": 2.444640874862671, "D": 2.610618829727173, "E": 2.5580241680145264}, "ranked_options": [{"letter": "B", "text": "MR Brain > MR thoracic/lumbar spine > CT chest/abdomen/pelvis > CT Thoracic Spine > CT Thoracic Spine > CT chest/abdomen/pelvis > Abdominal ultrasound > MR Spine > Whole-body PET/CT > Liver MRI", "avg_nll": 1.7155495882034302}, {"letter": "A", "text": "MR spine > MR Head > CT Thoracic Spine > CT Whole Body", "avg_nll": 2.3911921977996826}, {"letter": "C", "text": "MR cervical spine > MR Head > CT Whole Body > CT Thoracic Spine", "avg_nll": 2.444640874862671}, {"letter": "E", "text": "CT Thoracic Spine > CT Whole Body > MR cervical spine > MR Head", "avg_nll": 2.5580241680145264}, {"letter": "D", "text": "MR Brain > CT Thoracic Spine > MR cervical spine > CT Whole Body", "avg_nll": 2.610618829727173}], "correct_answer_letter": "B", "error": null, "method": "local"}
{"id": "patient_01_q8", "query": "Mrs. Sample’ medications changed between admission and discharge. Which of the following statements is correct?", "options_scores": {"A": 1.6707806587219238, "B": 2.6481704711914062, "C": 1.1297099590301514, "D": 2.7627170085906982, "E": 2.4790568351745605}, "ranked_options": [{"letter": "C", "text": "The dose of Sertraline hydrochloride was increased from 50 mg to 100 mg.", "avg_nll": 1.1297099590301514}, {"letter": "A", "text": "Aspirin was discontinued.", "avg_nll": 1.6707806587219238}, {"letter": "E", "text": "The patient started taking 2mg of Melatonin in the evening.", "avg_nll": 2.4790568351745605}, {"letter": "B", "text": "The patient started taking Pregabalin 50 mg, 1-0-0-0", "avg_nll": 2.6481704711914062}, {"letter": "D", "text": "The patient started taking prednisolone and is recommended to continue taking it for the rest of her life.", "avg_nll": 2.7627170085906982}], "correct_answer_letter": "E", "error": null, "method": "local"}
{"id": "patient_01_q9", "query": "Based on the medication changes from admission to discharge, which of the following best describes the Mrs Sample's evolving clinical situation?", "options_scores": {"A": 1.9343621730804443, "B": 2.3126184940338135, "C": 2.4529755115509033, "D": 2.0301878452301025, "E": 2.5849387645721436}, "ranked_options": [{"letter": "A", "text": "The patient's cardiovascular risk was decreased, leading to a reduced number of cardiovascular medications at discharge.", "avg_nll": 1.9343621730804443}, {"letter": "D", "text": "The patient's mood disorder was deemed stabilized, leading to the discontinuation of Sertraline at discharge.", "avg_nll": 2.0301878452301025}, {"letter": "B", "text": "The patient's pain management was escalated, as indicated by an increased frequency of Hydromorphone intake.", "avg_nll": 2.3126184940338135}, {"letter": "C", "text": "The patient developed a new gastrointestinal issue, hence the introduction of Pantoprazole at discharge.", "avg_nll": 2.4529755115509033}, {"letter": "E", "text": "The patient's immobility concerns were resolved, leading to the discontinuation of Enoxaparin sodium (Clexane®) at discharge.", "avg_nll": 2.5849387645721436}], "correct_answer_letter": "B", "error": null, "method": "local"}
